Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5), a biopharmaceutical company specializing in therapies for central and peripheral nervous system diseases, announced that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026 held today. The approvals included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members.
The motions on the agenda for the extraordinary part of the meeting were not put to vote due to the required quorum not being reached. Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected Board members, looking forward to their contributions. He also thanked Patrick Langlois and Luca Benatti, who stepped down after long-standing service.
Newron focuses on innovative treatments for central and peripheral nervous system disorders. Its lead compound, evenamide, is a first-in-class glutamate modulator being developed as an add-on therapy for treatment-resistant schizophrenia (TRS). The global pivotal ENIGMA-TRS Phase III program is ongoing, with clinical results showing significant improvements in efficacy measures and a favorable safety profile. Newron has partnerships with EA Pharma for Japan and other Asian territories, and Myung In Pharm for South Korea. The company's marketed product, Xadago®/safinamide, is approved for Parkinson's disease in multiple regions, including the EU, US, and Japan, commercialized by partners Zambon, Supernus Pharmaceuticals, and Meiji Seika.
For more information, visit www.newron.com. View the original release on www.newmediawire.com.
